Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
weifuchun
- Development stage
- Phase 4
- Lead developer
- Shanghai Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Weifuchun is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Hangzhou Huqingyutang Pharmaceutical, primarily used for the treatment of chronic atrophic gastritis (CAG) and the prevention of gastric precancerous lesions. The formulation typically consists of Red Ginseng (Hongshen), Isatis Root (Banlangen), and Sanchi (Sanqi). It is designed to invigorate the spleen, benefit qi, and resolve blood stasis. Mechanistically, Weifuchun is thought to improve gastric mucosal blood flow, promote the repair of damaged mucosa, and inhibit the progression of intestinal metaplasia and atypical hyperplasia. Clinical research has also explored its effects on the JAK2/STAT3 signaling pathway, which is involved in gastric carcinogenesis. It is available in tablet and capsule forms and is often used as a standard control or adjunctive therapy in clinical trials for gastric diseases in China.
- Brand names
- Weifuchun
- Other names
- WFCWeiFuChunPian胃复春胃复春片胃复春胶囊
02
Targets
CDX2 (Caudal type homeobox 2)SOX2 (SRY-box transcription factor 2)BMP4 (Bone morphogenetic protein 2)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on weifuchun.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on weifuchun.